biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Could The Ellipses Leak Force a Plan B?

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 14, 2023 1:50pm

101 Views

Post# 35223359

RE:RE:RE:RE:RE:RE:RE:Could The Ellipses Leak Force a Plan B?

Does this HER3 SunRock therapeutic pose any threat to the HER2+ therapeutic, xB3-001? Does the HER3 therapeutic have any capabilities in the CNS for brain tumours? As a fusion protein, it's a very large molecule, and wouldn't think it could cross the BBB in significant quantities.

If this HER3 treatment could cross the BBB into the CNS then it should be expected that Ellipses and SunRock would tout that somewhere in their literature.

The deal was announced a couple of weeks before the Ellipses leak. Maybe the Ellipses deal had already fallen through and the leak was of an old document describing it as already done.

But the two therapies do not appear to overlap or compete. The case can be made for doing both deals, HER2+ and HER3.

The question about whether Bioasis was delaying deals to facilitate the Midatech deal remains open.

jd

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management